ZA200710813B - Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins - Google Patents

Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins

Info

Publication number
ZA200710813B
ZA200710813B ZA200710813A ZA200710813A ZA200710813B ZA 200710813 B ZA200710813 B ZA 200710813B ZA 200710813 A ZA200710813 A ZA 200710813A ZA 200710813 A ZA200710813 A ZA 200710813A ZA 200710813 B ZA200710813 B ZA 200710813B
Authority
ZA
South Africa
Prior art keywords
mpps
treating
prostate
modified pore
cells
Prior art date
Application number
ZA200710813A
Other languages
English (en)
Inventor
Buckley James Thomas
Original Assignee
Protox Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protox Therapeutics Inc filed Critical Protox Therapeutics Inc
Publication of ZA200710813B publication Critical patent/ZA200710813B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
ZA200710813A 2005-06-14 2007-12-12 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins ZA200710813B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69026905P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
ZA200710813B true ZA200710813B (en) 2008-10-29

Family

ID=37531919

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710813A ZA200710813B (en) 2005-06-14 2007-12-12 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins

Country Status (15)

Country Link
US (2) US8916161B2 (xx)
EP (1) EP1891093B1 (xx)
JP (1) JP5220594B2 (xx)
KR (1) KR101365538B1 (xx)
CN (1) CN101238145B (xx)
AT (1) ATE502954T1 (xx)
AU (1) AU2006257664B2 (xx)
CA (1) CA2611839C (xx)
DE (1) DE602006020867D1 (xx)
DK (1) DK1891093T3 (xx)
ES (1) ES2366380T3 (xx)
IL (1) IL188143A (xx)
NZ (1) NZ564954A (xx)
WO (1) WO2006133553A1 (xx)
ZA (1) ZA200710813B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2366380T3 (es) 2005-06-14 2011-10-19 Protox Therapeutics Incorporated Método para el tratamiento o prevención de hiperplasia prostática benigna utilizando proteínas formadoras de poros modificadas.
EP2386639A3 (en) * 2005-11-21 2012-05-30 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
WO2007140618A1 (en) * 2006-06-09 2007-12-13 Protox Therapeutics Incorporated Modified protein toxins targeting cytokine -receptor bearing cells and use thereof for treating disease
US20100196951A1 (en) * 2007-07-12 2010-08-05 University Of Medicine And Dentistry Of New Jersey Antitoxin Destabilization Technology
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
JP2012512183A (ja) * 2008-12-15 2012-05-31 プロトックス セラピューティクス インコーポレイテッド 改変された孔形成性タンパク質プロアエロリシンを用いた前立腺炎の処置のための方法
EP2494400B1 (en) 2009-10-28 2021-12-08 Alentic Microscience Inc. Microscopy imaging
US9075225B2 (en) 2009-10-28 2015-07-07 Alentic Microscience Inc. Microscopy imaging
AU2011316786A1 (en) * 2010-10-22 2013-05-02 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US20140044812A1 (en) * 2012-08-07 2014-02-13 Kuwait Institute For Scientific Research Anesthetic and therapeutic composition for use in aquaculture
US10502666B2 (en) * 2013-02-06 2019-12-10 Alentic Microscience Inc. Sample processing improvements for quantitative microscopy
JP2016531282A (ja) 2013-06-26 2016-10-06 アレンティック マイクロサイエンス インコーポレイテッド 顕微鏡法に関するサンプル処理の改善
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
ES2773296T3 (es) * 2013-10-23 2020-07-10 Gemvax & Kael Co Ltd Composición para tratar y prevenir la hiperplasia prostática benigna
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110033449B (zh) * 2019-04-15 2023-06-27 苏州金唯智生物科技有限公司 电泳图的识别方法、装置、设备及存储介质
JP2022121814A (ja) * 2021-02-09 2022-08-22 国立大学法人神戸大学 藻類抑制剤

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
EP0753071A1 (en) 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5777078A (en) 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6066319A (en) 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5798218A (en) 1996-09-24 1998-08-25 University Of British Columbia Innovation And Development Corporation Compositions and methods for the specific detection of thy-1 antigen
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2001504334A (ja) 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6545131B1 (en) 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
US6265540B1 (en) 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1999002175A1 (en) 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CN1147317C (zh) 1997-08-15 2004-04-28 赛福伦公司 含酪氨酸激酶抑制剂和化学阉割剂的组合物及其用于制药的用途
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
WO1999036778A1 (en) 1998-01-20 1999-07-22 University Of Victoria Innovation & Development Corporation Detection of gpi anchored proteins
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
WO2000061613A2 (en) 1999-04-09 2000-10-19 The Johns Hopkins University Channel forming toxins as antiviral agents
US6179831B1 (en) * 1999-04-29 2001-01-30 Galil Medical Ltd. Method of cryoablating benign prostate hyperplasia
EP1052287A3 (en) 1999-05-10 2003-07-09 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
EP1052288A1 (en) 1999-05-10 2000-11-15 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
WO2001009165A2 (en) 1999-07-29 2001-02-08 The Johns Hopkins University ACTIVATION OF PEPTIDE PRODRUGS BY hK2
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
US6200573B1 (en) * 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
CA2408707C (en) * 2000-05-15 2010-04-13 Celgene Corp. Compositions and methods for the treatment of cancer
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
FI116467B (fi) 2000-09-29 2005-11-30 Licentia Oy Uudet peptidiligandit
AU2002223316A1 (en) 2000-11-07 2002-05-21 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
WO2002058578A1 (en) * 2000-11-13 2002-08-01 Wit Ip Corporation Treatment catheters with thermally insulated regions
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
US7456146B2 (en) 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
EP2518142B1 (en) 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
WO2004060915A2 (en) * 2002-12-03 2004-07-22 Sloan-Kettering Institute For Cancer Research Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
CN100341569C (zh) * 2004-09-17 2007-10-10 温州三天制药有限公司 一种治疗前列腺增生症的复方蛋白酶药物及制备方法
ES2366380T3 (es) 2005-06-14 2011-10-19 Protox Therapeutics Incorporated Método para el tratamiento o prevención de hiperplasia prostática benigna utilizando proteínas formadoras de poros modificadas.

Also Published As

Publication number Publication date
KR101365538B1 (ko) 2014-02-21
AU2006257664A1 (en) 2006-12-21
EP1891093A1 (en) 2008-02-27
IL188143A0 (en) 2008-03-20
CN101238145B (zh) 2013-04-24
JP2008546650A (ja) 2008-12-25
AU2006257664B2 (en) 2013-01-10
US20100233191A1 (en) 2010-09-16
CA2611839C (en) 2016-02-02
EP1891093B1 (en) 2011-03-23
JP5220594B2 (ja) 2013-06-26
KR20080042067A (ko) 2008-05-14
ATE502954T1 (de) 2011-04-15
US9950029B2 (en) 2018-04-24
US20160375095A1 (en) 2016-12-29
EP1891093A4 (en) 2008-10-01
CN101238145A (zh) 2008-08-06
NZ564954A (en) 2011-02-25
DK1891093T3 (da) 2011-07-11
ES2366380T3 (es) 2011-10-19
WO2006133553A1 (en) 2006-12-21
CA2611839A1 (en) 2006-12-21
DE602006020867D1 (de) 2011-05-05
IL188143A (en) 2012-10-31
US8916161B2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
ZA200710813B (en) Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
UA98629C2 (ru) Соединения и способ модуляции киназ
EP1887976A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER DISORDERS
EA201301350A1 (ru) Модифицированные полипептиды фактора vii и их применение
HK1118579A1 (en) Adamts13-comprising compositions having thrombolytic activity
GB2434983A (en) Methods and compositions for wound healing
EP1775343A8 (en) Anticancer agent containing dendritic cell having rna virus transferred thereinto
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MX346924B (es) Compuestos de diarilhidantoina.
WO2011020120A3 (en) Multi-transgenic pigs for diabetes treatment
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP2386639A3 (en) Modified pore-forming protein toxins and use thereof
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
MX2007010659A (es) Regimenes de dosificacion para trans-clomifeno.
WO2007100675A3 (en) Collagenase for treating cellulite
MX2008009579A (es) Metodo para el tratamiento de dolor neuropatico.
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
MX2007000050A (es) Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
WO2005020927A3 (en) Method of promoting graft survival with anti-tissue factor antibodies
WO2005089426A3 (en) Method of treating sepsis
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2007141661A3 (en) Herbal compositions for the prevention or treatment of benign prostatic hyperplasia
WO2007110705A3 (en) Macrolide as inhibitors of mhc class ii